Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 140

1.

Dissolution of Silver Nanoparticles in Colloidal Consumer Products: Effects of Particle Size and Capping Agent.

Radwan IM, Gitipour A, Potter PM, Dionysiou DD, Al-Abed SR.

J Nanopart Res. 2019 Jul 9;21(7):1-155. doi: 10.1007/s11051-019-4597-z.

PMID:
32184700
2.

Transformation of Silver Nanoparticle Consumer Products during Simulated Usage and Disposal.

Potter PM, Navratilova J, Rogers KR, Al-Abed SR.

Environ Sci Nano. 2019;6(2):592-598.

3.

Inhibition of carboxylesterase-1 alters clopidogrel metabolism and disposition.

Laizure SC, Hu ZY, Potter PM, Parker RB.

Xenobiotica. 2020 Mar;50(3):245-251. doi: 10.1080/00498254.2019.1612535. Epub 2019 May 15.

PMID:
31039046
4.

Role of Fe2O3 in fly ash surrogate on PCDD/Fs formation from 2-monochlorophenol.

Guan X, Ghimire A, Potter PM, Lomnicki SM.

Chemosphere. 2019 Jul;226:809-816. doi: 10.1016/j.chemosphere.2019.03.175. Epub 2019 Mar 29.

PMID:
30965252
5.

Distribution and Speciation of Copper and Arsenic in Rice Plants ( Oryza sativa japonica 'Koshihikari') Treated with Copper Oxide Nanoparticles and Arsenic during a Life Cycle.

Liu J, Wolfe K, Potter PM, Cobb GP.

Environ Sci Technol. 2019 May 7;53(9):4988-4996. doi: 10.1021/acs.est.9b00234. Epub 2019 Apr 15.

PMID:
30921519
6.

Correction to: Rapid and versatile pre-treatment for quantification of multi-walled carbon nanotubes in the environment using microwave-induced heating.

He Y, Al-Abed SR, Potter PM, Dionysiou DD.

Environ Sci Pollut Res Int. 2019 May;26(14):14013. doi: 10.1007/s11356-019-04828-5.

PMID:
30903480
7.

VOC Emissions and Formation Mechanisms from Carbon Nanotube Composites during 3D Printing.

Potter PM, Al-Abed SR, Lay D, Lomnicki SM.

Environ Sci Technol. 2019 Apr 16;53(8):4364-4370. doi: 10.1021/acs.est.9b00765. Epub 2019 Mar 26.

PMID:
30875473
8.

Clinical genome sequencing uncovers potentially targetable truncations and fusions of MAP3K8 in spitzoid and other melanomas.

Newman S, Fan L, Pribnow A, Silkov A, Rice SV, Lee S, Shao Y, Shaner B, Mulder H, Nakitandwe J, Shurtleff S, Azzato EM, Wu G, Zhou X, Barnhill R, Easton J, Nichols KE, Ellison DW, Downing JR, Pappo A, Potter PM, Zhang J, Bahrami A.

Nat Med. 2019 Apr;25(4):597-602. doi: 10.1038/s41591-019-0373-y. Epub 2019 Mar 4.

PMID:
30833747
9.

Rapid and versatile pre-treatment for quantification of multi-walled carbon nanotubes in the environment using microwave-induced heating.

He Y, Al-Abed SR, Potter PM, Dionysiou DD.

Environ Sci Pollut Res Int. 2019 May;26(14):13999-14012. doi: 10.1007/s11356-019-04229-8. Epub 2019 Feb 8. Erratum in: Environ Sci Pollut Res Int. 2019 Mar 23;:.

PMID:
30737716
10.

Corrigendum: Inhibition of SF3B1 by molecules targeting the spliceosome results in massive aberrant exon skipping.

Wu G, Fan L, Edmonson MN, Shaw T, Boggs K, Easton J, Rusch MC, Webb TR, Zhang J, Potter PM.

RNA. 2018 Dec;24(12):1886. doi: 10.1261/rna.068544.118. No abstract available.

11.

Potent, Irreversible Inhibition of Human Carboxylesterases by Tanshinone Anhydrides Isolated from Salvia miltiorrhiza ("Danshen").

Hatfield MJ, Binder RJ, Gannon R, Fratt EM, Bowling J, Potter PM.

J Nat Prod. 2018 Nov 26;81(11):2410-2418. doi: 10.1021/acs.jnatprod.8b00378. Epub 2018 Oct 23.

12.

Targeting ALK in pediatric RMS does not induce antitumor activity in vivo.

Wierdl M, Tsurkan L, Chi L, Hatfield MJ, Tollemar V, Bradley C, Chen X, Qu C, Potter PM.

Cancer Chemother Pharmacol. 2018 Aug;82(2):251-263. doi: 10.1007/s00280-018-3615-7. Epub 2018 May 31.

13.

Inhibition of SF3B1 by molecules targeting the spliceosome results in massive aberrant exon skipping.

Wu G, Fan L, Edmonson MN, Shaw T, Boggs K, Easton J, Rusch MC, Webb TR, Zhang J, Potter PM.

RNA. 2018 Aug;24(8):1056-1066. doi: 10.1261/rna.065383.117. Epub 2018 May 29. Erratum in: RNA. 2018 Dec;24(12):1886.

14.

Synergy of iron and copper oxides in the catalytic formation of PCDD/Fs from 2-monochlorophenol.

Potter PM, Guan X, Lomnicki SM.

Chemosphere. 2018 Jul;203:96-103. doi: 10.1016/j.chemosphere.2018.03.118. Epub 2018 Mar 20.

15.

Facile synthesis of 1,2-dione-containing abietane analogues for the generation of human carboxylesterase inhibitors.

Binder RJ, Hatfield MJ, Chi L, Potter PM.

Eur J Med Chem. 2018 Apr 10;149:79-89. doi: 10.1016/j.ejmech.2018.02.052. Epub 2018 Feb 19.

16.

Exploiting a water network to achieve enthalpy-driven, bromodomain-selective BET inhibitors.

Shadrick WR, Slavish PJ, Chai SC, Waddell B, Connelly M, Low JA, Tallant C, Young BM, Bharatham N, Knapp S, Boyd VA, Morfouace M, Roussel MF, Chen T, Lee RE, Kiplin Guy R, Shelat AA, Potter PM.

Bioorg Med Chem. 2018 Jan 1;26(1):25-36. doi: 10.1016/j.bmc.2017.10.042. Epub 2017 Nov 4.

17.

Optimization of a Neural Stem-Cell-Mediated Carboxylesterase/Irinotecan Gene Therapy for Metastatic Neuroblastoma.

Gutova M, Goldstein L, Metz M, Hovsepyan A, Tsurkan LG, Tirughana R, Tsaturyan L, Annala AJ, Synold TW, Wan Z, Seeger R, Anderson C, Moats RA, Potter PM, Aboody KS.

Mol Ther Oncolytics. 2016 Dec 14;4:67-76. doi: 10.1016/j.omto.2016.11.004. eCollection 2017 Mar 17.

18.

Selective Inhibitors of Human Liver Carboxylesterase Based on a β-Lapachone Scaffold: Novel Reagents for Reaction Profiling.

Hatfield MJ, Chen J, Fratt EM, Chi L, Bollinger JC, Binder RJ, Bowling J, Hyatt JL, Scarborough J, Jeffries C, Potter PM.

J Med Chem. 2017 Feb 23;60(4):1568-1579. doi: 10.1021/acs.jmedchem.6b01849. Epub 2017 Feb 7.

20.

Low-Temperature Catalytic Decomposition of 130 Tetra- to Octa-PCDD/Fs Congeners over CuOX and MnOX Modified V2O5/TiO2-CNTs with the Assistance of O3.

Zhao R, Jin D, Yang H, Lu S, Potter PM, Du C, Peng Y, Li X, Yan J.

Environ Sci Technol. 2016 Oct 18;50(20):11424-11432. doi: 10.1021/acs.est.6b02977. Epub 2016 Oct 7.

PMID:
27668311
21.

Tumour-selective targeting of drug metabolizing enzymes to treat metastatic cancer.

Wierdl M, Tsurkan L, Hatfield MJ, Potter PM.

Br J Pharmacol. 2016 Oct;173(19):2811-8. doi: 10.1111/bph.13553. Epub 2016 Aug 22. Review.

22.

Carboxylesterases: General detoxifying enzymes.

Hatfield MJ, Umans RA, Hyatt JL, Edwards CC, Wierdl M, Tsurkan L, Taylor MR, Potter PM.

Chem Biol Interact. 2016 Nov 25;259(Pt B):327-331. doi: 10.1016/j.cbi.2016.02.011. Epub 2016 Feb 15. Review.

23.

Contribution of aluminas and aluminosilicates to the formation of PCDD/Fs on fly ashes.

Potter PM, Dellinger B, Lomnicki SM.

Chemosphere. 2016 Feb;144:2421-6. doi: 10.1016/j.chemosphere.2015.11.009. Epub 2015 Nov 23.

24.

Pharmacodynamic assays to facilitate preclinical and clinical development of pre-mRNA splicing modulatory drug candidates.

Shi Y, Joyner AS, Shadrick W, Palacios G, Lagisetti C, Potter PM, Sambucetti LC, Stamm S, Webb TR.

Pharmacol Res Perspect. 2015 Aug;3(4):e00158. doi: 10.1002/prp2.158. Epub 2015 Jun 26.

25.

Targeting the DNA repair pathway in Ewing sarcoma.

Stewart E, Goshorn R, Bradley C, Griffiths LM, Benavente C, Twarog NR, Miller GM, Caufield W, Freeman BB 3rd, Bahrami A, Pappo A, Wu J, Loh A, Karlström Å, Calabrese C, Gordon B, Tsurkan L, Hatfield MJ, Potter PM, Snyder SE, Thiagarajan S, Shirinifard A, Sablauer A, Shelat AA, Dyer MA.

Cell Rep. 2014 Nov 6;9(3):829-41. doi: 10.1016/j.celrep.2014.09.028. Epub 2014 Oct 23.

26.

Sudemycin E influences alternative splicing and changes chromatin modifications.

Convertini P, Shen M, Potter PM, Palacios G, Lagisetti C, de la Grange P, Horbinski C, Fondufe-Mittendorf YN, Webb TR, Stamm S.

Nucleic Acids Res. 2014 Apr;42(8):4947-61. doi: 10.1093/nar/gku151. Epub 2014 Mar 11.

27.

Targeting oxidative stress in embryonal rhabdomyosarcoma.

Chen X, Stewart E, Shelat AA, Qu C, Bahrami A, Hatley M, Wu G, Bradley C, McEvoy J, Pappo A, Spunt S, Valentine MB, Valentine V, Krafcik F, Lang WH, Wierdl M, Tsurkan L, Tolleman V, Federico SM, Morton C, Lu C, Ding L, Easton J, Rusch M, Nagahawatte P, Wang J, Parker M, Wei L, Hedlund E, Finkelstein D, Edmonson M, Shurtleff S, Boggs K, Mulder H, Yergeau D, Skapek S, Hawkins DS, Ramirez N, Potter PM, Sandoval JA, Davidoff AM, Mardis ER, Wilson RK, Zhang J, Downing JR, Dyer MA; St. Jude Children’s Research Hospital–Washington University Pediatric Cancer Genome Project.

Cancer Cell. 2013 Dec 9;24(6):710-24. doi: 10.1016/j.ccr.2013.11.002.

28.

Neural stem cell-mediated delivery of irinotecan-activating carboxylesterases to glioma: implications for clinical use.

Metz MZ, Gutova M, Lacey SF, Abramyants Y, Vo T, Gilchrist M, Tirughana R, Ghoda LY, Barish ME, Brown CE, Najbauer J, Potter PM, Portnow J, Synold TW, Aboody KS.

Stem Cells Transl Med. 2013 Dec;2(12):983-92. doi: 10.5966/sctm.2012-0177. Epub 2013 Oct 28.

29.

Toxicology and Biodistribution Studies for MGH2.1, an Oncolytic Virus that Expresses Two Prodrug-activating Genes, in Combination with Prodrugs.

Kasai K, Nakashima H, Liu F, Kerr S, Wang J, Phelps M, Potter PM, Goins WB, Fernandez SA, Chiocca EA.

Mol Ther Nucleic Acids. 2013 Aug 6;2:e113. doi: 10.1038/mtna.2013.38.

30.

Control of RhoA methylation by carboxylesterase I.

Cushman I, Cushman SM, Potter PM, Casey PJ.

J Biol Chem. 2013 Jun 28;288(26):19177-83. doi: 10.1074/jbc.M113.467407. Epub 2013 May 8.

31.

Modulation of esterified drug metabolism by tanshinones from Salvia miltiorrhiza ("Danshen").

Hatfield MJ, Tsurkan LG, Hyatt JL, Edwards CC, Lemoff A, Jeffries C, Yan B, Potter PM.

J Nat Prod. 2013 Jan 25;76(1):36-44. doi: 10.1021/np300628a. Epub 2013 Jan 3.

32.

Fe2O3 nanoparticle mediated molecular growth and soot inception from the oxidative pyrolysis of 1-methylnaphthalene.

Herring MP, Potter PM, Wu H, Lomnicki S, Dellinger B.

Proc Combust Inst. 2013;34(1):1749-1757.

33.

Inhibition of human carboxylesterases hCE1 and hiCE by cholinesterase inhibitors.

Tsurkan LG, Hatfield MJ, Edwards CC, Hyatt JL, Potter PM.

Chem Biol Interact. 2013 Mar 25;203(1):226-30. doi: 10.1016/j.cbi.2012.10.018. Epub 2012 Nov 2.

34.

Covalent inhibition of recombinant human carboxylesterase 1 and 2 and monoacylglycerol lipase by the carbamates JZL184 and URB597.

Crow JA, Bittles V, Borazjani A, Potter PM, Ross MK.

Biochem Pharmacol. 2012 Nov 1;84(9):1215-22. doi: 10.1016/j.bcp.2012.08.017. Epub 2012 Aug 27.

35.

The development and application of small molecule modulators of SF3b as therapeutic agents for cancer.

Webb TR, Joyner AS, Potter PM.

Drug Discov Today. 2013 Jan;18(1-2):43-9. doi: 10.1016/j.drudis.2012.07.013. Epub 2012 Aug 3. Review.

36.

High payload dual therapeutic-imaging nanocarriers for triggered tumor delivery.

Kim JK, Yuan H, Nie J, Yang YT, Leggas M, Potter PM, Rinehart J, Jay M, Lu X.

Small. 2012 Sep 24;8(18):2895-903. doi: 10.1002/smll.201200437. Epub 2012 Jul 6.

37.

ATP-dependent mitochondrial porphyrin importer ABCB6 protects against phenylhydrazine toxicity.

Ulrich DL, Lynch J, Wang Y, Fukuda Y, Nachagari D, Du G, Sun D, Fan Y, Tsurkan L, Potter PM, Rehg JE, Schuetz JD.

J Biol Chem. 2012 Apr 13;287(16):12679-90. doi: 10.1074/jbc.M111.336180. Epub 2012 Jan 31.

38.

Global and local molecular dynamics of a bacterial carboxylesterase provide insight into its catalytic mechanism.

Yu X, Sigler SC, Hossain D, Wierdl M, Gwaltney SR, Potter PM, Wadkins RM.

J Mol Model. 2012 Jun;18(6):2869-83. doi: 10.1007/s00894-011-1308-9. Epub 2011 Nov 30.

39.

Inhibition of recombinant human carboxylesterase 1 and 2 and monoacylglycerol lipase by chlorpyrifos oxon, paraoxon and methyl paraoxon.

Crow JA, Bittles V, Herring KL, Borazjani A, Potter PM, Ross MK.

Toxicol Appl Pharmacol. 2012 Jan 1;258(1):145-50. doi: 10.1016/j.taap.2011.10.017. Epub 2011 Nov 4.

40.

Requirements for mammalian carboxylesterase inhibition by substituted ethane-1,2-diones.

Parkinson EI, Jason Hatfield M, Tsurkan L, Hyatt JL, Edwards CC, Hicks LD, Yan B, Potter PM.

Bioorg Med Chem. 2011 Aug 1;19(15):4635-43. doi: 10.1016/j.bmc.2011.06.012. Epub 2011 Jul 4.

41.

Carboxylesterase inhibitors.

Hatfield MJ, Potter PM.

Expert Opin Ther Pat. 2011 Aug;21(8):1159-71. doi: 10.1517/13543776.2011.586339. Epub 2011 May 24. Review.

42.

Immobilization of active human carboxylesterase 1 in biomimetic silica nanoparticles.

Edwards JS, Kumbhar A, Roberts A, Hemmert AC, Edwards CC, Potter PM, Redinbo MR.

Biotechnol Prog. 2011 May-Jun;27(3):863-9. doi: 10.1002/btpr.604. Epub 2011 Apr 20.

43.

Nerve agent hydrolysis activity designed into a human drug metabolism enzyme.

Hemmert AC, Otto TC, Chica RA, Wierdl M, Edwards JS, Lewis SM, Edwards CC, Tsurkan L, Cadieux CL, Kasten SA, Cashman JR, Mayo SL, Potter PM, Cerasoli DM, Redinbo MR.

PLoS One. 2011 Mar 18;6(3):e17441. doi: 10.1371/journal.pone.0017441. Erratum in: PLoS One. 2012;7(1). doi:10.1371/annotation/c5953f27-95f8-4a1b-a46c-639d90e182ac. Lewis, Steven L [corrected to Lewis, Steven M].

44.

Sudemycins, novel small molecule analogues of FR901464, induce alternative gene splicing.

Fan L, Lagisetti C, Edwards CC, Webb TR, Potter PM.

ACS Chem Biol. 2011 Jun 17;6(6):582-9. doi: 10.1021/cb100356k. Epub 2011 Mar 7.

45.

Structure-activity relationships of substituted 1-pyridyl-2-phenyl-1,2-ethanediones: potent, selective carboxylesterase inhibitors.

Young BM, Hyatt JL, Bouck DC, Chen T, Hanumesh P, Price J, Boyd VA, Potter PM, Webb TR.

J Med Chem. 2010 Dec 23;53(24):8709-15. doi: 10.1021/jm101101q. Epub 2010 Nov 24.

46.

Inactivation of lipid glyceryl ester metabolism in human THP1 monocytes/macrophages by activated organophosphorus insecticides: role of carboxylesterases 1 and 2.

Xie S, Borazjani A, Hatfield MJ, Edwards CC, Potter PM, Ross MK.

Chem Res Toxicol. 2010 Dec 20;23(12):1890-904. doi: 10.1021/tx1002194.

47.

Mouse serum paraoxonase-1 lactonase activity is specific for medium-chain length fatty acid lactones.

Connelly PW, Picardo CM, Potter PM, Teiber JF, Maguire GF, Ng DS.

Biochim Biophys Acta. 2011 Jan;1811(1):39-45. doi: 10.1016/j.bbalip.2010.10.002. Epub 2010 Oct 29.

PMID:
21044894
48.

Recommended nomenclature for five mammalian carboxylesterase gene families: human, mouse, and rat genes and proteins.

Holmes RS, Wright MW, Laulederkind SJ, Cox LA, Hosokawa M, Imai T, Ishibashi S, Lehner R, Miyazaki M, Perkins EJ, Potter PM, Redinbo MR, Robert J, Satoh T, Yamashita T, Yan B, Yokoi T, Zechner R, Maltais LJ.

Mamm Genome. 2010 Oct;21(9-10):427-41. doi: 10.1007/s00335-010-9284-4. Epub 2010 Oct 8.

49.

Organ-specific carboxylesterase profiling identifies the small intestine and kidney as major contributors of activation of the anticancer prodrug CPT-11.

Hatfield MJ, Tsurkan L, Garrett M, Shaver TM, Hyatt JL, Edwards CC, Hicks LD, Potter PM.

Biochem Pharmacol. 2011 Jan 1;81(1):24-31. doi: 10.1016/j.bcp.2010.09.001. Epub 2010 Sep 15.

50.

Biochemical and molecular analysis of carboxylesterase-mediated hydrolysis of cocaine and heroin.

Hatfield MJ, Tsurkan L, Hyatt JL, Yu X, Edwards CC, Hicks LD, Wadkins RM, Potter PM.

Br J Pharmacol. 2010 Aug;160(8):1916-28. doi: 10.1111/j.1476-5381.2010.00700.x.

Supplemental Content

Loading ...
Support Center